PCSK9 modulates phenotype, proliferation and migration of smooth muscle cells in response to PDGF-BB

Introduction: Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) represents the most recent pharmacological target for the treatment of severe hypercholesterolemia, due to its action on hepatic low-density lipoprotein receptor (LDLR) [1, 2]. Secreted PCSK9 derives mainly from the liver, but other tissues, such as intestine, pancreas, kidney and brain express PCSK9 at significant levels [3]. PCSK9 is also found in Smooth Muscle Cells (SMC) present in human atherosclerotic plaques [4]. In addition, the absence of PCSK9 determines a partial protection to neointimal formation in response to perivascular manipulation in mice [5].
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research